Recent developments highlight promising drug candidates and clinical trials in oncology. Minghui Pharmaceutical secured $131 million pre-IPO financing to advance PD-1/VEGF bispecific antibodies and antibody-drug conjugates. The MIRINAE trial evaluates adjuvant atezolizumab plus capecitabine in triple-negative breast cancer to improve outcomes in this challenging subtype. Novel NSD2 inhibitor KTX-2001 received FDA IND clearance, broadening epigenetic therapy options. Furthermore, compounds enhancing auranofin efficacy and CDK1/CDK2 targeting strategies represent advancing therapeutic modalities. These efforts collectively expand the armamentarium against diverse malignancies.